ProMIS Neurosciences Appoints Josh Mandel-Brehm, Senior Biotechnology Executive, to Board of Directors
TORONTO and CAMBRIDGE, Mass., September 1, 2021 (GLOBE NEWSWIRE) – ProMIS Neurosciences, Inc. (TSX: PMN); (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of therapeutic antibodies selectively targeting toxic oligomers involved in the development of neurodegenerative diseases, today announced the appointment of Josh Mandel-Brehm to its board of administration with immediate effect.
“I am delighted to welcome Josh Mandel-Brehm as a member of the ProMIS Board of Directors at this time,” said Eugene Williams, Executive Chairman of ProMIS Neurosciences. “Josh has built a productive platform business in CAMP4, whose experience is very relevant to ProMIS and our unique platform opportunity. Combined with his extensive experience in business development, capital formation and strategy, we believe Josh will make a significant contribution to the ProMIS Board of Directors.
“I am very happy to join the ProMIS Board of Directors,” said Josh Mandel-Brehm. “PMN310 has the potential to change the lives of many patients with Alzheimer’s disease and I am particularly impressed with the technology platform and the team. ProMIS is well positioned to build a portfolio of next-generation differentiated antibody therapies in neurodegenerative and other misfolded protein diseases, an area that I believe will be of increasing interest to investors and large pharmaceutical companies. .
Josh Mandel-Brehm is President and CEO of CAMP4 Therapeutics and serves a dual mandate as an Entrepreneur Partner with Polaris Partners. He is also a co-founder and member of the board of directors of Vico Therapeutics, an oligonucleotide-based RNA modulation company focused on developing therapies for patients with rare CNS disorders.
Mr. Mandel-Brehm previously held key business development and operations management positions at leading biotechnology companies. Most recently, he was part of the Biogen Business Development Group, where he led several strategic activities and related transactions, including the expansion of Biogen’s non-malignant hematology franchise, overseeing fundamental investments to enter the field of ophthalmology and the advancement of Biogen’s gene therapy strategy. Prior to Biogen, Mr. Mandel-Brehm held several increasingly senior positions at Genzyme as a member of the business development group of the company’s rare disease business unit.
Mr. Mandel-Brehm holds a BA in Biology from Washington University in St. Louis and an MBA from the University of Michigan.
About ProMIS Neurosciences, Inc.
ProMIS Neurosciences, Inc. is a developmental biotechnology company focused on the discovery and development of therapeutic antibodies selectively targeting toxic oligomers involved in the development and progression of neurodegenerative diseases, particularly Alzheimer’s disease (AD ), amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD). The Company’s exclusive target discovery engine is based on the use of two complementary techniques. The company applies its thermodynamic computational discovery platform -ProMIS ™ and collective coordinates – to predict new targets known as disease-specific epitopes on the molecular surface of misfolded proteins. Using this unique approach, the Company is developing novel therapeutic antibodies for AD, ALS and PD. ProMIS is headquartered in Toronto, Ontario, and offices in Cambridge, Massachusetts. ProMIS is listed on the Toronto Stock Exchange under the symbol PMN and on the OTCQB Venture Market under the symbol ARFXF.
For more information on ProMIS Neurosciences, please visit the Company’s website at: www.promisneurosciences.com
For Investor Relations, please contact:
Alpine Equity Advisors
Nicolas Rigopulos, president
Phone. 617 901-0785
The TSX has not reviewed and accepts no responsibility for the adequacy or accuracy of this release. This information release contains certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements to differ materially from those involved in these statements, and therefore, such statements should not be interpreted. as guarantees of performance or future results. All forward-looking statements are based on the Company’s current beliefs as well as on assumptions made by and information currently available and on other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to the risks and uncertainties, including the risks and uncertainties identified by the Company in its filings of government securities, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.